I 
2,155
-6.71%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in KRW, from our data supplier.
Revenue
₩4.38bn
FY2021FY2025
Net income
−₩3.80bn
FY2021FY2025
Free cash flow
−₩6.73bn
FY2021FY2025
Shareholders' equity
₩27.64bn
FY2021FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | ₩4.38bn | ₩3.56bn | ₩4.50bn | ₩1.34bn | ₩527.0m |
| Research and development | ₩693.1m | ₩704.3m | ₩261.8m | ₩567.7m | ₩526.7m |
| Operating income | −₩4.15bn | −₩4.30bn | −₩4.54bn | — | −₩2.66bn |
| Net income | −₩3.80bn | −₩4.00bn | −₩5.04bn | −₩9.74bn | −₩2.62bn |
| Diluted earnings per share | -251.50 | -265.40 | -337.01 | -650.52 | -206.92 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Total assets | ₩30.23bn | ₩34.89bn | ₩16.53bn | ₩19.15bn | ₩6.95bn |
| Cash and short-term investments | — | ₩22.55bn | ₩8.06bn | ₩11.99bn | — |
| Total liabilities | ₩2.59bn | ₩3.61bn | ₩3.71bn | ₩39.16bn | ₩17.37bn |
| Debt | ₩678.3m | ₩1.74bn | ₩2.13bn | ₩2.38bn | ₩1.50bn |
| Shareholders' equity | ₩27.64bn | ₩31.27bn | ₩12.82bn | −₩20.02bn | −₩10.42bn |
| Shares outstanding | 15m | 15m | 15m | 15m | 13m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩4.25bn | −₩6.93bn | −₩3.45bn | −₩4.08bn | −₩3.53bn |
| Capital spending | −₩2.48bn | −₩663.9m | −₩496.0m | −₩422.2m | −₩1.39bn |
| Free cash flow | −₩6.73bn | −₩7.59bn | −₩3.94bn | −₩4.50bn | −₩4.92bn |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩2.98bn | ₩76.8m | ₩1.85bn | ₩1.65bn | ₩721.6m | ₩150.2m | ₩2.06bn | ₩596.1m |
| Operating income | −₩195.2m | −₩1.46bn | −₩744.7m | −₩703.5m | −₩1.18bn | −₩1.52bn | −₩361.8m | −₩1.62bn |
| Net income | −₩114.1m | −₩1.36bn | −₩619.2m | −₩588.1m | −₩1.19bn | −₩1.41bn | −₩123.9m | −₩1.61bn |
| Diluted earnings per share | -7.55 | -89.97 | -40.95 | -38.95 | -78.62 | -93.29 | -8.21 | -107.04 |
| Cash from operations | −₩14.0m | −₩874.0m | −₩651.0m | −₩746.0m | −₩1.29bn | −₩1.56bn | −₩6.93bn | −₩5.93bn |
| Capital spending | −₩9.0m | −₩83.0m | −₩1.98bn | −₩22.0m | −₩116.0m | −₩361.0m | −₩663.0m | −₩518.0m |
| Free cash flow | −₩23.0m | −₩957.0m | −₩2.63bn | −₩768.0m | −₩1.41bn | −₩1.92bn | −₩7.59bn | −₩6.45bn |
| Total assets | ₩28.72bn | ₩29.07bn | ₩30.23bn | ₩31.61bn | ₩32.26bn | ₩33.63bn | ₩34.89bn | ₩34.90bn |
| Cash and short-term investments | — | — | — | — | — | ₩20.57bn | ₩22.55bn | ₩23.78bn |
| Debt | ₩606.9m | ₩642.6m | ₩678.3m | ₩714.0m | ₩791.3m | ₩1.64bn | ₩1.74bn | ₩1.81bn |
| Shareholders' equity | ₩26.17bn | ₩26.28bn | ₩27.64bn | ₩28.23bn | ₩28.81bn | ₩29.98bn | ₩31.27bn | ₩31.33bn |
Financial ratios
Data as of 15 Sept 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Operating margin | -94.9% | -120.7% | -101.0% | — | -504.5% |
| Net margin | -86.9% | -112.3% | -112.2% | -727.7% | -497.3% |
| Return on equity | -13.8% | -12.8% | -39.3% | 48.6% | 25.2% |
| Return on assets | -12.6% | -11.5% | -30.5% | -50.8% | -37.7% |
| Revenue growth | 22.8% | -20.7% | 236.0% | 153.9% | — |
| Earnings growth | -5.0% | -20.6% | -48.2% | 271.5% | — |
| Current ratio | 19.66x | 18.16x | 8.22x | 0.38x | 0.13x |
| Debt to equity | 0.02x | 0.03x | 0.10x | -0.07x | -0.14x |
| Equity ratio | 91.4% | 89.6% | 77.5% | -104.5% | -149.8% |
| Interest coverage | -25.86x | -23.32x | -2.83x | — | -2.31x |
| R&D as a share of sales | 15.8% | 19.8% | 5.8% | 42.4% | 99.9% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 48.4% | — | — |
| Net income | -26.9% | — | — |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | |
|---|---|---|
| Price to earnings | -13.1 | -18.0 |
| Price to sales | 11.4 | 20.2 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.